Tracey Sacco Sells 30,000 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Tracey Sacco sold 30,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $25.62, for a total value of $768,600.00. Following the transaction, the insider now owns 49,285 shares in the company, valued at $1,262,681.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $29.49 on Wednesday. Scholar Rock Holding Co. has a 12-month low of $6.48 and a 12-month high of $35.38. The company has a market cap of $2.35 billion, a PE ratio of -14.11 and a beta of 0.82. The stock has a 50 day simple moving average of $9.64 and a 200-day simple moving average of $10.87. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.01. During the same period last year, the business posted ($0.47) EPS. On average, equities research analysts forecast that Scholar Rock Holding Co. will post -2.39 EPS for the current year.

Hedge Funds Weigh In On Scholar Rock

Several large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Scholar Rock by 16.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock valued at $156,444,000 after acquiring an additional 1,149,519 shares in the last quarter. Redmile Group LLC boosted its stake in Scholar Rock by 0.3% during the 1st quarter. Redmile Group LLC now owns 6,419,610 shares of the company’s stock valued at $114,012,000 after purchasing an additional 17,105 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Scholar Rock by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after purchasing an additional 114,550 shares during the period. Bellevue Group AG raised its stake in shares of Scholar Rock by 1.5% in the 4th quarter. Bellevue Group AG now owns 2,168,925 shares of the company’s stock worth $40,776,000 after buying an additional 31,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Scholar Rock by 31.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,430,764 shares of the company’s stock valued at $26,898,000 after buying an additional 342,690 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SRRK shares. BMO Capital Markets raised their price target on shares of Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. HC Wainwright raised their target price on shares of Scholar Rock from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Wedbush upped their target price on Scholar Rock from $27.00 to $37.00 and gave the company an “outperform” rating in a report on Monday. Finally, JPMorgan Chase & Co. cut their price target on Scholar Rock from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, October 3rd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $27.75.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.